Vaxcyte Surges 32% on Positive Phase 3 Data for VAX-31 Pneumonia Vaccine

Pfizer is enforcing a Belgian court judgment against Poland and Romania over unpaid COVID-19 vaccine orders by targeting an unusual source of leverage: air traffic control fees. Eurocontrol, the intergovernmental body that coordinates European air traffic management, has frozen transfers of airline route charges owed to Poland's and Romania's air navigation agencies after Pfizer moved to enforce an April court ruling requiring the two countries to pay a combined roughly $2.1 billion for vaccine doses they declined to accept under a 2021 European Union contract. The Brussels court rejected Poland's and Romania's arguments for abandoning their pandemic-era purchase commitments and ordered them to accept and pay for €1.9 billion, or about $2.2 billion, of Pfizer-BioNTech vaccines, with Poland accounting for €1.3 billion of that amount and Romania for €600 million. Eurocontrol has already withheld air-navigation fees from Poland and imposed a precautionary seizure tied to Romania, though Poland's air traffic agency says airline fees provide more than 80% of its income and Polish and Romanian aviation authorities have warned that freezing those funds could threaten essential operations and air safety. Both countries are challenging the rulings, and Romania's health minister said the ruling remains enforceable during an appeal.

Pfizer Inc. and BioNTech SE announced on August 27 that the U.S. FDA has approved the supplemental Biologics License Application for their 2026–2027 COVID-19 vaccine formula, COMIRNATY XFG. The updated formula targets the XFG variant and is authorized for adults aged 65 and older, as well as individuals aged 5 to 64 with high-risk underlying conditions. The approval, based on clinical, real-world, and manufacturing data showing strong immune responses against circulating strains, aligns with FDA strain guidance for fall 2026. For Pfizer, the clearance protects a recurring seasonal revenue stream that supports margins and cash flow while the company funds its non-COVID pipeline and manages upcoming loss-of-exclusivity events. For BioNTech, it validates the execution power of its proprietary mRNA platform and preserves its balance sheet, which carries minimal debt and substantial cash reserves to fund late-stage oncology trials without dilutive financing. Both companies still face long-term market contraction as COVID-19 booster demand has normalized well below pandemic peaks, leaving Pfizer's earnings less predictable against elevated debt and exposing BioNTech's heavy operating losses as vaccine revenues fall short of its massive R&D expenses.